查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1520462

2024-2032 年按技術、生物材料、應用和地區分類的神經調節市場報告

Neuromodulation Market Report by Technology, Biomaterial, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球神經調節市場規模達74億美元。在強勁投資的支持下，慢性疾病和神經系統疾病的盛行率不斷上升、有利的監管環境、醫療保健支出不斷增加、設備技術的顯著進步以及對微創(MI) 療法的需求不斷成長，推動了該市場正在經歷強勁成長研究與開發 (R&D) 計劃。

神經調節市場分析：

主要市場促進因素：神經調節市場是由慢性疾病和神經系統疾病（如帕金森氏症、慢性疼痛和憂鬱症）日益普及所驅動。此外，醫療保健支出的不斷增加、改善報銷政策的有利法規的實施以及神經調節設備的快速技術進步（包括磁振造影（MRI）安全和可充電設備的開發）正在推動市場成長。

主要市場趨勢：目前有一種趨勢是將人工智慧 (AI) 和機器學習 (ML) 技術整合到神經調節設備中，以實現即時監測和調整治療。此外，在正在進行的研究和成功的臨床試驗的推動下，神經調節療法適應症的擴大正在擴大市場的規模。

地理趨勢：北美因其先進的醫療基礎設施、健全的監管框架和高昂的醫療支出而在神經調節市場佔據主導地位。在醫療基礎設施改善、可支配收入增加以及對神經調節療法認知不斷增強的推動下，其他地區也在經歷快速成長。

競爭格局：神經調節產業的一些主要市場參與者包括 Abbott Laboratories、Bioventus Inc.、Boston Scientific Corporation、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、Medtronic plc、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc .、Nevro Corp. 等。

挑戰和機會：主要挑戰是設備和程序的高成本，這可能限制市場滲透，特別是在發展中地區。此外，設備植入的複雜性和潛在的副作用也構成了障礙。然而，機會在於神經調節應用範圍的擴大，包括針對肥胖和成癮等尚未開發的醫療狀況的潛在治療方法。此外，醫療保健支出的增加為市場擴展到以前服務不足的地區提供了重要機會。

神經調節市場趨勢：

慢性病和神經系統疾病的盛行率上升

糖尿病、肥胖症和心血管疾病等慢性疾病以及帕金森氏症、癲癇和憂鬱症等神經系統疾病的發生率上升，是神經調節市場的重要驅動力。根據疾病管制與預防中心 (CDC) 的數據，美國十分之六的成年人患有慢性病。十分之四的人患有兩種以上的慢性病。此外，印度約 21% 的老年人患有至少一種慢性病。農村地區 17% 的老年人和城市地區 29% 的老年人患有至少一種慢性病。這些健康問題會導致併發症，但可以透過神經調節療法來控制或治療。例如，脊髓刺激 (SCS) 廣泛用於緩解背部手術失敗症候群或複雜區域疼痛症候群引起的疼痛。

醫療保健支出增加

由於醫療保健支出不斷增加、中產階級人口不斷成長以及先進醫療基礎設施的建立，全球多個國家擴大採用神經調節療法。例如，印度醫療保健公共支出在 2023 會計年度佔 GDP 的 2.1%，在 2022 會計年度佔 GDP 的 2.2%。此外，印度政府還計劃推出價值盧比的信貸獎勵計畫。 5000 億盧比（68 億美元）用於加強該國的醫療基礎設施。同樣，在歐洲，2022 年政府整體醫療支出達到 12,210 億歐元，佔 GDP 的 7.7%。這種擴張正在擴大神經調節產業的地理足跡，並將這些先進的療法引入新的患者群體。

落實優惠報銷政策

神經調節手術報銷政策的持續改善是推動市場成長的主要因素。在許多國家，健康保險公司已經修改了他們的政策，將幾種神經調節療法納入其中，因為他們認知到神經調節療法在治療許多難治性疾病方面的益處。這些變化使神經調節技術更容易為更廣泛的患者所使用。根據美國人口普查局的數據，到 2022 年，美國 92.1% 的人（即 3.040 億人）在一年中的某個時候擁有健康保險。此外，私人醫療保險覆蓋率比公共醫療保險覆蓋率更高，分別為 65.6% 和 36.1%。此外，保險公司正在認知到神經調節的長期成本效益，特別是在減少住院時間和藥物使用方面，這正在擴大報銷範圍。

神經調節市場細分：

IMARC Group提供了每個細分市場的主要趨勢分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據技術、生物材料和應用對市場進行了分類。

按技術分類：

內部神經調節

脊髓刺激 (SCS)

深部腦部刺激 (DBS)

迷走神經刺激 (VNS)

薦神經刺激 (SNS)

胃電刺激 (GES)

外部神經調節

經皮電神經刺激 (TENS)

經顱磁刺激 (TMS)

其他

內部神經調節佔據大部分市場佔有率

該報告基於該技術對市場進行了詳細的細分和分析。這包括內部神經調節（脊髓刺激（SCS）、深部腦部刺激（DBS）、迷走神經刺激（VNS）、骶神經刺激（SNS）和胃電刺激（GES））和外部神經調節（經皮神經電刺激） TENS）、經顱磁刺激（TMS）等）。根據該報告，內部神經調節代表了最大的部分。

根據神經調節市場分析和預測，內部神經調節成為最大的細分市場。它包括先進的療法，例如脊髓刺激（SCS）、深部腦部刺激（DBS）、骶神經刺激（SNS）和迷走神經刺激（VNS）等。它們用於治療多種慢性病和神經系統疾病，包括慢性疼痛、帕金森氏症、尿失禁和大便失禁以及難治性癲癇。此外，內部神經調節在改善患者治療效果方面的有效性已得到證實，設備技術的顯著進步提高了使用者的安全性和舒適度，以及臨床應用範圍的擴大正在推動神經調節市場的收入。

依生物材料分類：

金屬生物材料

高分子生物材料

陶瓷生物材料

金屬生物材料產業佔比最大

報告還提供了基於生物材料的市場的詳細細分和分析。這包括金屬生物材料、聚合生物材料和陶瓷生物材料。報告稱，金屬生物材料佔據最大的市場佔有率。

根據神經調節市場報告和概述，金屬生物材料脫穎而出，成為最大的細分市場，因為它們在神經調節治療中使用的植入物和設備（例如電極和導線）的製造中發揮關鍵作用。金屬生物材料因其卓越的導電性、生物相容性和耐用性而受到青睞。它們對於確保神經調節裝置的長期可靠性和性能至關重要，特別是那些需要長期植入或受到體液和組織影響的裝置。除此之外，提高其功能和安全性的持續進步，例如增強生物相容性的塗層或降低感染風險的技術，有利於神經調節市場的成長。

按應用分類：

帕金森氏症

癲癇

沮喪

肌張力失調

疼痛管理

其他

帕金森氏症代表領先的細分市場

該報告根據應用程式提供了詳細的市場細分和分析。這包括帕金森氏症、癲癇、憂鬱症、肌張力失調、疼痛管理等。根據該報告，帕金森氏症佔最大部分。

根據神經調節市場前景和趨勢，帕金森氏症成為最大的細分市場，反映了神經調節療法在治療慢性神經疾病方面的重大影響和效用。擴大使用深部腦部刺激（DBS）來治療對藥物治療沒有充分反應的患者，這促進了市場的成長。 DBS有助於緩解震顫、僵硬和運動遲緩等症狀，顯著提高患者的生活品質。此外，神經調節在提供實質和持續的症狀緩解方面的功效，導致其在臨床環境中的廣泛採用，正在促進神經調節的市場佔有率。

按地區分類：

北美洲

美國

加拿大

亞太

中國

日本

印度

韓國

澳洲

印尼

其他

歐洲

德國

法國

英國

義大利

西班牙

俄羅斯

其他

拉丁美洲

巴西

墨西哥

其他

中東和非洲

北美市場領先，佔據最大的神經調節市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是神經調節最大的區域市場。

北美佔據了神經調節市場最大的佔有率，這歸因於幾個關鍵因素，包括先進的醫療基礎設施、強力的監管支持以及對研發 (R&D) 的大量投資。此外，該地區是神經調節行業中一些領先公司的中心，透過不斷的技術進步推動創新和市場成長。此外，慢性病和神經系統疾病的高盛行率，加上有利於早期採用新技術的完善的醫療保健系統，正在為神經調節市場收入做出貢獻。

競爭格局：

市場研究報告也對市場競爭格局進行了全面分析。也提供了所有主要公司的詳細資料。神經調節產業的一些主要市場參與者包括 Abbott Laboratories、Bioventus Inc.、Boston Scientific Corporation、Helius Medical Technologies、Integer Holdings Corporation、LivaNova PLC、Medtronic plc、MicroTransponder Inc.、Neuronetics、NeuroPace Inc.、NeuroSigma Inc.、內夫羅公司等

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

頂級神經調節公司致力於透過合併、收購和合作等策略性措施來增強其競爭優勢。他們正在投資研發 (R&D)，以創新和改進其神經調節設備。這些創新的重點是提高慢性疼痛、帕金森氏症和泌尿系統疾病等疾病治療的準確性、有效性和安全性。此外，產業領導者參與臨床試驗，以擴大現有技術的適應症，從而擴大潛在的用戶群。他們還優先考慮在新市場獲得監管批准，以確保全球獲得其先進療法。此外，大公司正在透過數位平台加強患者和從業者的參與，以促進更好地監測和管理治療結果。這有助於他們適應醫療技術數位健康解決方案的更廣泛趨勢，從而對神經調節市場的近期發展和機會產生積極影響。

神經調節市場新聞：

2022 年 4 月，波士頓科學公司（美國）的 Vercise Neural Navigator 和視覺化軟體 STIMVIEW XT 獲得 FDA 批准。該設備可讓醫療專業人員查看帕金森氏症患者和接受深部腦部刺激（DBS）患者的引線或電極的即時位置。

2022 年 12 月，雅培實驗室的 Eterna 脊髓刺激 (SCS) 系統獲得 FDA 批准。它是一種小型植入式可充電脊髓刺激器，用於治療慢性疼痛。此神經調節裝置利用 Abbott 專有的低劑量 BurstDR 刺激。

本報告回答的關鍵問題：

  • 迄今為止，全球神經調節市場表現如何，未來幾年將如何表現？
  • 全球神經調節市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球神經調節市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的神經調節市場？
  • 什麼是基於技術的市場分割？
  • 神經調節市場上最具吸引力的技術是什麼？
  • 基於生物材料的市場區隔是什麼？
  • 神經調節市場上最具吸引力的生物材料是什麼？
  • 基於應用程式的市場區隔是什麼？
  • 神經調節市場中最具吸引力的應用是什麼？
  • 市場競爭結構如何？
  • 全球神經調節市場的主要參與者/公司有哪些？

本報告回答的關鍵問題：

  • 迄今為止，全球神經調節市場表現如何，未來幾年將如何表現？
  • 全球神經調節市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球神經調節市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的神經調節市場？
  • 什麼是基於技術的市場分割？
  • 神經調節市場上最具吸引力的技術是什麼？
  • 基於生物材料的市場區隔是什麼？
  • 神經調節市場上最具吸引力的生物材料是什麼？
  • 基於應用程式的市場區隔是什麼？
  • 神經調節市場中最具吸引力的應用是什麼？
  • 市場競爭結構如何？
  • 全球神經調節市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球神經調節市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依技術

  • 內部神經調節
    • 市場走向
    • 關鍵環節
      • 脊髓刺激 (SCS)
      • 深部腦部刺激 (DBS)
      • 迷走神經刺激 (VNS)
      • 薦神經刺激 (SNS)
      • 胃電刺激 (GES)
    • 市場預測
  • 外部神經調節
    • 市場走向
    • 關鍵環節
      • 經皮電神經刺激 (TENS)
      • 經顱磁刺激 (TMS)
      • 其他
    • 市場預測

第 7 章：市場區隔：依生物材料

  • 金屬生物材料
    • 市場走向
    • 市場預測
  • 高分子生物材料
    • 市場走向
    • 市場預測
  • 陶瓷生物材料
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按應用

  • 帕金森氏症
    • 市場走向
    • 市場預測
  • 癲癇
    • 市場走向
    • 市場預測
  • 沮喪
    • 市場走向
    • 市場預測
  • 肌張力失調
    • 市場走向
    • 市場預測
  • 疼痛管理
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • Bioventus Inc.
    • Boston Scientific Corporation
    • Helius Medical Technologies
    • Integer Holdings Corporation
    • LivaNova PLC
    • Medtronic plc
    • MicroTransponder Inc.
    • Neuronetics
    • NeuroPace Inc.
    • NeuroSigma Inc.
    • Nevro Corp.
Product Code: SR112024A5722

The global neuromodulation market size reached US$ 7.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2032, exhibiting a growth rate (CAGR) of 9.7% during 2024-2032. The market is experiencing robust growth, driven by the increasing prevalence of chronic and neurological disorders, imposition of favorable regulatory environment, rising expenditure on healthcare, significant advancements in device technology, and growing demand for minimally invasive (MI) therapies, supported by strong investment in research and development (R&D) initiatives.

Neuromodulation Market Analysis:

Major Market Drivers: The neuromodulation market is driven by the increasing prevalence of chronic diseases and neurological disorders, such as Parkinson's disease, chronic pain, and depression. Moreover, the rising expenditure on healthcare, the implementation of favorable regulations that offer improvements in reimbursement policies, and rapid technological advancements in neuromodulation devices, including the development of magnetic resonance imaging (MRI)-safe and rechargeable devices, are boosting the market growth.

Key Market Trends: There is a trend towards the integration of artificial intelligence (AI) and machine learning (ML) technologies into neuromodulation devices that enable real-time monitoring and adjustments of therapy. Moreover, the expansion of indications for neuromodulation therapies, facilitated by ongoing research and successful clinical trials, is broadening the market expansion.

Geographical Trends: North America dominates the neuromodulation market due to its advanced healthcare infrastructure, robust regulatory framework, and high healthcare expenditure. Other regions are also experiencing rapid growth, driven by improving healthcare infrastructures, increasing disposable incomes, and growing awareness of neuromodulation therapies.

Competitive Landscape: Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., and Nevro Corp., among many others.

Challenges and Opportunities: A major challenge is the high cost of devices and procedures, which can limit market penetration, especially in developing regions. Additionally, the complexity of device implantation and potential side effects pose hurdles. However, opportunities lie in the expanding scope of neuromodulation applications, including potential treatments for untapped medical conditions, such as obesity and addiction. Furthermore, increasing healthcare spending presents a significant opportunity for market expansion into previously underserved areas.

Neuromodulation Market Trends:

Rising Prevalence of Chronic Diseases and Neurological Disorders

The heightened incidence of chronic diseases such as diabetes, obesity, and cardiovascular conditions, alongside neurological disorders like Parkinson's disease, epilepsy, and depression, is a significant driver for the neuromodulation market. As per the Centre for Disease Control and Prevention (CDC), 6 in 10 adults in the U.S. are suffering from chronic diseases. And 4 out of 10 people have more than two chronic conditions. Also, about 21% of the geriatric adults in India have at least one chronic disease. 17% of geriatric people in rural areas and 29% in urban areas suffer from at least one chronic disease. These health issues lead to complications that can be managed or treated through neuromodulation therapies. For instance, spinal cord stimulation (SCS) is widely used for pain relief in conditions that result from failed back surgery syndrome or complex regional pain syndrome.

Increasing Expenditure on Healthcare

Several countries across the globe are witnessing increased adoption of neuromodulation therapies owing to rising expenditure on healthcare, the growing population of the middle class, and the establishment of advanced healthcare infrastructures. For instance, India's public expenditure on healthcare touched 2.1% of GDP in FY23 and 2.2% in FY22. Also, the Indian government is planning to introduce a credit incentive program worth Rs. 50,000 crores (US$ 6.8 billion) to boost the country's healthcare infrastructure. Similarly, in Europe, the general government spending on health amounted to €1221 billion or 7.7% of GDP in 2022. The U.S. healthcare spending saw a hike of 4.1%, reaching $4.5 trillion or $13493/person. This expansion is increasing the geographical footprint of the neuromodulation industry and introducing these advanced therapies to new patient populations.

Implementation of Favorable Reimbursement Policies

The ongoing improvements in reimbursement policies for neuromodulation procedures is a main factor driving the market growth. In many countries, health insurance providers have revised their policies to include several neuromodulation therapies as they recognize their benefits in treating many refractory conditions. These changes have made neuromodulation technologies more accessible to a broader range of patients. In 2022, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during the year, as per the U.S. Census Bureau. Moreover, private health insurance coverage was more prevalent than public coverage, at 65.6 percent and 36.1 percent, respectively. Also, insurers are recognizing the cost-effectiveness of neuromodulation in the long term, especially in terms of reduced hospital stays and medication use, which is expanding the scope of reimbursement coverage.

Neuromodulation Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on technology, biomaterial, and application.

Breakup by Technology:

Internal Neuromodulation

Spinal Cord Stimulation (SCS)

Deep Brain Stimulation (DBS)

Vagus Nerve Stimulation (VNS)

Sacral Nerve Stimulation (SNS)

Gastric Electrical Stimulation (GES)

External Neuromodulation

Transcutaneous Electrical Nerve Stimulation (TENS)

Transcranial Magnetic Stimulation (TMS)

Others

Internal neuromodulation accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes internal neuromodulation (spinal cord stimulation (SCS), deep brain stimulation (DBS), vagus nerve stimulation (VNS), sacral nerve stimulation (SNS), and gastric electrical stimulation (GES)) and external neuromodulation (transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), and others). According to the report, internal neuromodulation represented the largest segment.

Based on the neuromodulation market analysis and forecast, internal neuromodulation emerged as the largest segment. It includes advanced therapies, such as spinal cord stimulation (SCS), deep brain stimulation (DBS), sacral nerve stimulation (SNS), and vagus nerve stimulation (VNS), among others. They are utilized for treating a wide range of chronic conditions and neurological disorders, including chronic pain, Parkinson's disease, urinary and fecal incontinence, and refractory epilepsy. Moreover, the proven efficacy of internal neuromodulations in improving patient outcomes, significant advancements in device technology that enhance user safety and comfort, and the broadening scope of clinical applications are fueling the neuromodulation market revenue.

Breakup by Biomaterial:

Metallic Biomaterials

Polymeric Biomaterials

Ceramic Biomaterials

Metallic biomaterials hold the largest share of the industry

A detailed breakup and analysis of the market based on the biomaterial have also been provided in the report. This includes metallic biomaterials, polymeric biomaterials, and ceramic biomaterials. According to the report, metallic biomaterials accounted for the largest market share.

As per the neuromodulation market report and overview, metallic biomaterials stand out as the largest segment, owing to their critical role in the manufacturing of implants and devices used in neuromodulation therapies, such as electrodes and leads. Metallic biomaterials are favored for their superior electrical conductivity, biocompatibility, and durability. They are essential for ensuring the long-term reliability and performance of neuromodulation devices, particularly those that require chronic implantation or are subject to bodily fluids and tissues. Besides this, the ongoing advancements that improve their functionality and safety, such as coatings to enhance biocompatibility or technologies to reduce the risk of infection, are favoring the neuromodulation market growth.

Breakup by Application:

Parkinson's Disease

Epilepsy

Depression

Dystonia

Pain Management

Others

Parkinson's disease represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes Parkinson's disease, epilepsy, depression, dystonia, pain management, and others. According to the report, Parkinson's disease represented the largest segment.

According to the neuromodulation market outlook and trends, Parkinson's disease emerged as the largest segment, reflecting the significant impact and utility of neuromodulation therapies in managing chronic neurological disorders. The increasing utilization of deep brain stimulation (DBS) for the treatment of patients who do not respond adequately to pharmacological treatments is enhancing the market growth. DBS helps in alleviating symptoms such as tremors, rigidity, and bradykinesia, significantly enhancing the quality of life for patients. Moreover, the efficacy of neuromodulation in providing substantial and sustained symptom relief, leading to its widespread adoption in clinical settings, is catalyzing the neuromodulation market share.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest neuromodulation market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for neuromodulation.

North America accounted for the largest segment in the neuromodulation market, attributed to several key factors, including advanced healthcare infrastructure, strong regulatory support, and substantial investments in research and development (R&D). Moreover, the region is a hub of some of the leading companies in the neuromodulation industry, which drives innovation and market growth through continuous advancements in technology. Additionally, the high prevalence of chronic diseases and neurological disorders, coupled with a well-established healthcare system that facilitates early adoption of new technologies, is contributing to the neuromodulation market revenue.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the neuromodulation industry include Abbott Laboratories, Bioventus Inc., Boston Scientific Corporation, Helius Medical Technologies, Integer Holdings Corporation, LivaNova PLC, Medtronic plc, MicroTransponder Inc., Neuronetics, NeuroPace Inc., NeuroSigma Inc., Nevro Corp., etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

The top neuromodulation companies are engaged in enhancing their competitive edge through strategic initiatives, such as mergers, acquisitions, and partnerships. They are investing in research and development (R&D) to innovate and improve their neuromodulation devices. These innovations focus on increasing the precision, effectiveness, and safety of therapies for conditions like chronic pain, Parkinson's disease, and urinary disorders. Additionally, industry leaders are involved in clinical trials to expand the indications for existing technologies, thereby broadening the potential user base. They are also prioritizing obtaining regulatory approvals in new markets to ensure global access to their advanced therapies. Furthermore, major companies are enhancing patient and practitioner engagement through digital platforms that facilitate better monitoring and management of therapy outcomes. This helps them align with the broader trend toward digital health solutions in medical technology, thereby positively impacting the neuromodulation market's recent development and opportunities.

Neuromodulation Market News:

In April 2022, Boston Scientific Corporation (US) received FDA approval for its Vercise Neural Navigator with visualization software, STIMVIEW XT. The device allows medical professionals to view the real-time location of leads, or electrodes, in patients with Parkinson's disease and those undergoing deep brain stimulation (DBS).

In December 2022, Abbott Laboratories received FDA approval for its Eterna spinal cord stimulation (SCS) system. It is a small implantable and rechargeable spinal cord stimulator for treating chronic pain. The neuromodulation device utilizes Abbott's proprietary low-dose BurstDR stimulation.

Key Questions Answered in This Report:

  • How has the global neuromodulation market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global neuromodulation market?
  • What is the impact of each driver, restraint, and opportunity on the global neuromodulation market?
  • What are the key regional markets?
  • Which countries represent the most attractive neuromodulation market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the neuromodulation market?
  • What is the breakup of the market based on biomaterial?
  • Which is the most attractive biomaterial in the neuromodulation market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the neuromodulation market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global neuromodulation market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Neuromodulation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Internal Neuromodulation
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Spinal Cord Stimulation (SCS)
      • 6.1.2.2 Deep Brain Stimulation (DBS)
      • 6.1.2.3 Vagus Nerve Stimulation (VNS)
      • 6.1.2.4 Sacral Nerve Stimulation (SNS)
      • 6.1.2.5 Gastric Electrical Stimulation (GES)
    • 6.1.3 Market Forecast
  • 6.2 External Neuromodulation
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Transcutaneous Electrical Nerve Stimulation (TENS)
      • 6.2.2.2 Transcranial Magnetic Stimulation (TMS)
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Biomaterial

  • 7.1 Metallic Biomaterials
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Polymeric Biomaterials
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Ceramic Biomaterials
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Parkinson's Disease
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Epilepsy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Depression
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dystonia
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Pain Management
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bioventus Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Boston Scientific Corporation
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Helius Medical Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Integer Holdings Corporation
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 LivaNova PLC
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Medtronic plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 MicroTransponder Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Neuronetics
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 NeuroPace Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
    • 14.3.11 NeuroSigma Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Nevro Corp.
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials

List of Figures

  • Figure 1: Global: Neuromodulation Market: Major Drivers and Challenges
  • Figure 2: Global: Neuromodulation Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Neuromodulation Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Neuromodulation Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Neuromodulation Market: Breakup by Biomaterial (in %), 2023
  • Figure 6: Global: Neuromodulation Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Neuromodulation Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Neuromodulation (Internal Neuromodulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Neuromodulation (Internal Neuromodulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Neuromodulation (External Neuromodulation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Neuromodulation (External Neuromodulation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Neuromodulation (Metallic Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Neuromodulation (Metallic Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Neuromodulation (Polymeric Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Neuromodulation (Polymeric Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Neuromodulation (Ceramic Biomaterials) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Neuromodulation (Ceramic Biomaterials) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Neuromodulation (Parkinson's Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Neuromodulation (Parkinson's Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Neuromodulation (Epilepsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Neuromodulation (Epilepsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Neuromodulation (Depression) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Neuromodulation (Depression) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Neuromodulation (Dystonia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Neuromodulation (Dystonia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Neuromodulation (Pain Management) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Neuromodulation (Pain Management) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Neuromodulation (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Neuromodulation (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: North America: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: North America: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: United States: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: United States: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Canada: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Canada: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia-Pacific: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia-Pacific: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: China: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: China: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Japan: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Japan: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: India: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: India: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: South Korea: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: South Korea: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Australia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Australia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Indonesia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Indonesia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Europe: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Europe: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Germany: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Germany: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: France: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: France: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: United Kingdom: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: United Kingdom: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Italy: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Italy: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Spain: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Spain: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Russia: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Russia: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Latin America: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Latin America: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Brazil: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Brazil: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Mexico: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Mexico: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Others: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Others: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Middle East and Africa: Neuromodulation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Middle East and Africa: Neuromodulation Market: Breakup by Country (in %), 2023
  • Figure 78: Middle East and Africa: Neuromodulation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Global: Neuromodulation Industry: SWOT Analysis
  • Figure 80: Global: Neuromodulation Industry: Value Chain Analysis
  • Figure 81: Global: Neuromodulation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Neuromodulation Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Neuromodulation Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Neuromodulation Market Forecast: Breakup by Biomaterial (in Million US$), 2024-2032
  • Table 4: Global: Neuromodulation Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Neuromodulation Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Neuromodulation Market: Competitive Structure
  • Table 7: Global: Neuromodulation Market: Key Players